News & Conferences

VaxForm, LLC Awarded STTR Grant by DoD

Jul 25, 2012 7:15 am

Release date:  July 25, 2012

            Bethlehem, PA:  VaxForm has been awarded a Phase I STTR grant to develop a recombinant fusion protein vaccine targeting diseases resulting from Streptococcus pyogenes infection.  S. pyogenes, is a Gram-positive bacterium that causes a wide variety of diseases such as strep throat, scarlet fever, necrotizing fasciitis, streptococcal toxic shock syndrome, and impetigo. Asymptomatic infections and carriage are also common features of S.pyogenes infection.  Worldwide an estimated 500,000 deaths annually are attributed to S.pyogenes infection. An effective vaccine could save thousands of lives and allow for billions of dollars in medical cost savings by reducing the rate of disease in the population. 

            The vaccine incorporates a recombinant protein fusion between Streptococcal pyrogenic exotoxin B (SpeB), and Streptococcal pyrogenic exotoxin A (SpeA).  Using VaxForm’s expertise and development strategy, a safe and effective vaccine can be rapidly developed to reduce the morbidity and mortality burden of disease as well as cost of medical treatment in both military and civilian populations.  

About VaxForm: VaxForm is a privately held limited liability company based in Bethlehem, Pennsylvania focusing on the development of vaccine products targeting global healthcare needs.  VaxForm also provides consulting services in the area of vaccine formulation development to assist organization in reaching effective solutions to achieve objectives in response to the spectrum of global health needs.